Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

5 in Phase 3

Quick facts

Phase 3 pipeline

Placebo of TQC2731
This is a placebo control arm and contains no active pharmaceutical ingredient.
Placebo of TQH2722 injection
This is a placebo control with no active pharmacological mechanism.
TQB2825 Injection · Oncology
TQB2825 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.
TQC2731 injection
TQC2731 injection's mechanism is not publicly available.
TQH2722 injection
TQH2722 injection's mechanism is not publicly available.

Phase 1 pipeline

TQB2934 injection

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

What is Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.'s pipeline?

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. has 5 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Placebo of TQC2731, Placebo of TQH2722 injection, TQB2825 Injection, TQC2731 injection.

Sector hub: All tracked pharma companies